Lipocalin 10 as a Therapeutic Agent for Inflammation-Induced Organ Dysfunction

 

2021-070
   
Technology Overview

Despite recent advances in antibiotic therapy and supportive critical care, sepsis remains a leading cause of death in intensive care units. Currently, the increased vascular permeability is well-recognized to be responsible for inflammation-/sepsis-triggered organ failure and patient mortality.

There is a positive connection between vascular leakage, cardiac depression, and mortality upon sepsis and other inflammation conditions. However, to date, no specific treatment targeting the vascular leak is yet available. Thus, a deeper understanding of mediators and their associated mechanisms in inflammation-/sepsis-triggered-induced vascular leak is of great importance for the development of future therapeutic strategies.

Dr. Fan and his team found a method of reducing the risk of an inflammation-/sepsis-triggered vascular leak, tissue edema or organ dysfunction in a subject. The compelling data suggest that Lcn10 may involve inflammation-/sepsis-induced cardiovascular leak, evidenced by deficiency of Lcn10 increases, whereas therapeutically administration of recombinant truncated Lcn10 protein, reduces cardiovascular permeability and organ injury.

Background

 

Advantages and Benefits
  • Reducing risk of sepsis-induced vascular leak
  • Compelling data suggesting Lcn10 may involve sepsis-induced cardiac vascular leak
  •  
  •  
  •  
  •  
Patents
Serial No. File Date Patent No. Issued Date
PCT/US2022/015480 2/7/2022    
3,210,691 8/4/2023    
18/276,122 8/7/2023    
Other Media
Inventor(s)
  • Xiaohong Wang
  • Yutian Li
  • Guo-Chang Fan
Contact
Rucha Tadwalkar
Licensing Associate
Lead Inventor